Applied DNA Sciences, Inc. develops and markets DNA-based technology solutions for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets; and for supply chain security, anti-counterfeiting, and anti-theft technology purposes applications in the United States, Europe, and Asia. The company's supply chain security and product authentication solutions include SigNature molecular tags that provide forensic power and protection for various applications and can be used to fortify brand protection efforts, and strengthen supply chain security, as well as mark, track, and convict criminals; SigNify IF portable DNA readers and SigNify consumable reagent test kits that provide definitive real-time authentication of molecular tags in the field; and CertainT Supply Chain Platform that provides proof of product claims for materials, items, or products. It also manufactures and sells COVID-19 PCR-based molecular diagnostic test kit under the LineaTM COVID-19 Assay Kit trademark; and non-diagnostic COVID-19 pooled surveillance testing to detect instances of COVID-19 in defined populations under the safeCircle trademark. In addition, the company provides preclinical contract research and manufacturing services for the nucleic acid-based therapeutic markets; and contract research services to RNA based drug and biologic customers for preclinical studies. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.
IPO Year:
Exchange: NASDAQ
Website: adnas.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/11/2022 | $8.00 → $6.00 | Buy | HC Wainwright & Co. |
| 8/13/2021 | $13.00 → $11.00 | Buy | HC Wainwright & Co. |
SC 13G - APPLIED DNA SCIENCES INC (0000744452) (Subject)
SC 13G/A - APPLIED DNA SCIENCES INC (0000744452) (Subject)
SC 13G/A - APPLIED DNA SCIENCES INC (0000744452) (Subject)
SC 13G - APPLIED DNA SCIENCES INC (0000744452) (Subject)
SC 13G/A - APPLIED DNA SCIENCES INC (0000744452) (Subject)
SC 13G/A - APPLIED DNA SCIENCES INC (0000744452) (Subject)
SC 13G/A - APPLIED DNA SCIENCES INC (0000744452) (Subject)
SC 13G - APPLIED DNA SCIENCES INC (0000744452) (Subject)
SC 13G - APPLIED DNA SCIENCES INC (0000744452) (Subject)
SC 13G/A - APPLIED DNA SCIENCES INC (0000744452) (Subject)
- Signals Start of New Commercialization Phase for LineaRx Subsidiary -- Company Negotiating GMP Supply Agreement -- Company Reaffirms Strategic Restructuring Timeline - STONY BROOK, NY / ACCESSWIRE / January 10, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the completion of the buildout of its new Good Manufacturing Practices (GMP) manufacturing facility (the "facility") within its Stony Brook, New York, headquarters and readiness to accept orders for the manufacture of LineaDNA™ IVT templates that clients can utilize for the production of mRNA clinical trial materials. The facility is undergoing fi
STONY BROOK, NY / ACCESSWIRE / January 8, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it has rescheduled its Investor Update call to Thursday, February 13, 2025, to coincide with the release of its first quarter fiscal 2025 financial results.The Company originally scheduled an Investor Update call for January 9, 2025, to update shareholders on its strategic restructuring announced in December 2024 and GMP initiative. The change reflects the observance of the National Day of Mourning in recognition of the passing of former President Jimmy Carter.About Applied DNA Sciences
- Regulatory Approval Showcases Clinical Advancement of Linea DNA™ as a Rapid and Effective Means of Producing CAR-T cell Therapies -STONY BROOK, NY / ACCESSWIRE / December 18, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, announced that the State Institute for Drug Control of the Czech Republic (SÚKL) approved an application for a Phase I clinical trial of an investigational CD123-specific autologous CAR T-cell therapy by the Institute of Hematology and Blood Transfusion (ÚHKT/Eng: IHBT) in Prague for the treatment of relapsed and/or refractory acute myeloid leukemia (AML). UHKT-CAR123-01 utilizes Applied DNA's synt
- Pursuing Divestiture of CertainT® Platform, Implements Changes to Corporate Leadership -- Build-out of GMP Manufacturing Facility to be Completed by January 9, 2025 -- Webcast and Conference Call Scheduled for Thursday, January 9, 2025, at 4:30 PM ET - STONY BROOK, NY / ACCESSWIRE / December 17, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today reported financial results for its fourth quarter and fiscal year ended September 30, 2024. An update on the buildout of the Company's GMP manufacturing facility is available for viewing via slideshow on the Presentations page of the Investor Relations portion of the Compa
STONY BROOK, NY / ACCESSWIRE / December 16, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its fourth quarter and fiscal year 2024 financial results after the market close on Tuesday, December 17, 2024.The Company will host a conference call for the investment community to coincide with an update on its GMP manufacturing facility build-out on Thursday, January 9, 2025, at 4:30 p.m. ET.Webcast and Conference Call Date & Time: Thursday, January 9 @ 4:30 p.m. ETDial In:Domestic callers (toll free): 844-887-9402International callers: 412-317-6798Canadian callers
STONY BROOK, NY / ACCESSWIRE / October 30, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the pricing of a registered direct offering and concurrent private placement with gross proceeds to the Company expected to be approximately $6.5 million before deducting placement agent fees and other estimated expenses payable by the Company.The offering is comprised of 20,312,500 shares (the "Shares") of the Company's common stock (or pre-funded warrants in lieu thereof) at a purchase price of $0.32 per share of common stock (or pre-funded warrants in lieu thereof, which shall have the same purchase price, less
STONY BROOK, NY / ACCESSWIRE / October 15, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA"), a leader in PCR-based DNA technologies, today announced that Dr. James A. Hayward, president and chief executive officer, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit. Maxim Group LLC is presenting the virtual summit from October 15th to 17th.Jason McCarthy, Ph.D., Maxim's senior managing director and head of Biotechnology Research, will interview Dr. Hayward.Applied DNA's fireside chat will be available for viewing by registered conference attendees on Wednesday, October 16, 2024.Details for the fireside chat are as follows:Date: Wednesday, October 1
STONY BROOK, NY / ACCESSWIRE / September 18, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that on September 17, 2024, it received a notification letter (the "Notification Letter") from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq"), informing the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement").As previously reported, the Company was notified on July 12, 2024, that its common stock failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as re
- Recurring and Accelerated Receipt of Order Reflects Customer Commitment to Linea DNA - STONY BROOK, NY / ACCESSWIRE / September 17, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced it has received a follow-on order valued at more than $500,000 for a quantity of Linea™ DNA from a global manufacturer of in vitro diagnostics (IVDs). The follow-on order was placed under a long-standing supply agreement for the bulk manufacture of Linea DNA (non-therapeutic) used in the manufacture of a cancer diagnostic test. Applied DNA expects to deliver on the order over four quarterly shipments in calendar 2025.Dr. Jam
- Co-Hosts Seminar with mRNA CDMO Kudo Bio to Demonstrate Linea IVT Capability for Rapid mRNA Manufacturing - STONY BROOK, NY / ACCESSWIRE / September 17, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced its participation at upcoming mRNA events in Boston this week:3rd Annual mRNA Process Development & Manufacturing Summit - members of Applied DNA's Biotherapeutics Sales and Business Development teams (collectively 'LineaRx,' a majority-owned Applied DNA company) will attend the 3rd Annual mRNA Process Development & Manufacturing Summit taking place September 17-19, 2024.LineaRx will present its Linea™ IVT platform - a com
HC Wainwright & Co. reiterated coverage of Applied DNA Sciences with a rating of Buy and set a new price target of $6.00 from $8.00 previously
HC Wainwright & Co. reiterated coverage of Applied DNA Sciences with a rating of Buy and set a new price target of $11.00 from $13.00 previously
HC Wainwright & Co. reiterated coverage of Applied DNA Sciences with a rating of Buy and set a new price target of $13.00 from $14.00 previously
ROTH Capital initiated coverage of Applied DNA Sciences with a rating of Buy and set a new price target of $24.00
Roth Capital initiated coverage of Applied DNA Sciences with a rating of Buy
DEF 14A - APPLIED DNA SCIENCES INC (0000744452) (Filer)
8-K - APPLIED DNA SCIENCES INC (0000744452) (Filer)
PRE 14A - APPLIED DNA SCIENCES INC (0000744452) (Filer)
8-K - APPLIED DNA SCIENCES INC (0000744452) (Filer)
8-K - APPLIED DNA SCIENCES INC (0000744452) (Filer)
8-K - APPLIED DNA SCIENCES INC (0000744452) (Filer)
8-K - APPLIED DNA SCIENCES INC (0000744452) (Filer)
10-Q - APPLIED DNA SCIENCES INC (0000744452) (Filer)
8-K - APPLIED DNA SCIENCES INC (0000744452) (Filer)
DEFA14A - APPLIED DNA SCIENCES INC (0000744452) (Filer)
Experienced Biopharma/Pharmaceutical Executive to Lead Implementation of cGMP-quality LineaDNA™ Capability for IVT mRNA ProductionPreviously Led Manufacturing Operations Scale-up for the BioNTech/Pfizer mRNA COVID-19 Vaccine at CDMO Division of Maravai LifeSciencesSTONY BROOK, NY / ACCESSWIRE / September 6, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the appointment of Beverly Wolgast, Ph.D., as executive director of Quality and cGMP Programs. Dr. Wolgast will oversee and manage Applied DNA's quality assurance and control and regulatory compliance spanning the Company's three business segments, incl
STONY BROOK, N.Y.--(BUSINESS WIRE)--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that Clay Shorrock, J.D., has rejoined the Company effective immediately to serve on the executive leadership team as Chief Legal Officer and Executive Director, Business Development. In this newly created role, Mr. Shorrock will lead Applied DNA’s legal, regulatory, IP, and business development functions. Dr. James A. Hayward, president and CEO, Applied DNA, said, “As we continue to advance the adoption of our PCR-based, LinearDNATM manufacturing platform across highly regulated markets and further devel
4 - APPLIED DNA SCIENCES INC (0000744452) (Issuer)
4 - APPLIED DNA SCIENCES INC (0000744452) (Issuer)
4 - APPLIED DNA SCIENCES INC (0000744452) (Issuer)
4 - APPLIED DNA SCIENCES INC (0000744452) (Issuer)
4 - APPLIED DNA SCIENCES INC (0000744452) (Issuer)
4 - APPLIED DNA SCIENCES INC (0000744452) (Issuer)
4 - APPLIED DNA SCIENCES INC (0000744452) (Issuer)
4 - APPLIED DNA SCIENCES INC (0000744452) (Issuer)
4 - APPLIED DNA SCIENCES INC (0000744452) (Issuer)
4 - APPLIED DNA SCIENCES INC (0000744452) (Issuer)
STONY BROOK, NY / ACCESSWIRE / December 16, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its fourth quarter and fiscal year 2024 financial results after the market close on Tuesday, December 17, 2024.The Company will host a conference call for the investment community to coincide with an update on its GMP manufacturing facility build-out on Thursday, January 9, 2025, at 4:30 p.m. ET.Webcast and Conference Call Date & Time: Thursday, January 9 @ 4:30 p.m. ETDial In:Domestic callers (toll free): 844-887-9402International callers: 412-317-6798Canadian callers
STONY BROOK, NY / ACCESSWIRE / August 7, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its third quarter fiscal 2024 financial results after market close on Thursday, August 8, 2024. In conjunction with this announcement, Applied DNA management will host a conference call for analysts and members of the investment community starting at 4:30 p.m. ET the same day. On this call, management will discuss the Company's financial results and recent accomplishments.Date & Time: Thursday, August 8 @ 4:30 p.m. ETDial In:Domestic callers (toll free): 844-887-9402Inter
STONY BROOK, NY / ACCESSWIRE / May 10, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced consolidated financial results for its second fiscal quarter ended March 31, 2024. The Company's Form 10-Q can be viewed at https://investors.adnas.com/sec-filings/. The Company will not host a financial webcast or call for this most recent quarterly reporting period. The Company will host an investor update call on June 12, 2024.Summary Second Quarter Fiscal 2024 Financial Results:Total revenues were approximately $930 thousand for the three-month period March 31, 2024, compared to $4.4 million for the second quarter
STONY BROOK, NY / ACCESSWIRE / February 5, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its first quarter fiscal 2024 financial results after market close on Thursday, February 8, 2024. In conjunction with this announcement, Applied DNA management will host a conference call for analysts and members of the investment community starting at 4:30 p.m. ET the same day. On this call, management will discuss the Company's financial results and recent accomplishments.Date & Time: Thursday, February 8 @ 4:30 p.m. ETDial In:Domestic callers (toll free): 844-887-940
- Conference Call/Webcast Scheduled for Today at 4:30 PM ET -STONY BROOK, NY / ACCESSWIRE / December 7, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced consolidated financial results for its fourth quarter ended September 30, 2023."Our fiscal fourth quarter concludes a productive year during which we took a number of critical steps that place us firmly in the execution phase of our pivot to a biotherapeutic manufacturing-first growth strategy," stated Dr. James A. Hayward, president and CEO of Applied DNA. "We closed on the strategic acquisition of Spindle Biotech that empowered the launch of our Linea™
STONY BROOK, NY / ACCESSWIRE / December 5, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its fourth quarter and full year financial results 2023 ended September 30, 2023, on Thursday, December 7, 2023, after the market close. The Company will host a conference call for the investment community to discuss the results and answer questions at 4:30 p.m. ET.Date & Time: Thursday, December 7 @ 4:30 p.m. ETDial In:Domestic callers (toll free): 844-887-9402International callers: 412-317-6798Canadian callers (toll free): 866-605-3852Live webcast: https://event.choru
Conference Call/Webcast Scheduled for Today at 4:30 PM ETSTONY BROOK, NY / ACCESSWIRE / August 10, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced consolidated financial results for the third quarter of fiscal 2023 ended June 30, 2023."Our fiscal third quarter performance stands out for the substantial progress made to advance the development and commercialization of our LinearDNA™ platform for biotherapeutic applications that culminated shortly after the close of the quarter with our acquisition of Spindle Biotech and launch of our Linea™ IVT platform for mRNA production," stated Dr. James A. Hayward,
STONY BROOK, NY / ACCESSWIRE / August 7, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release financial results for the three months ended June 30, 2023 after the market close on Thursday, August 10, 2023. The Company will host a conference call for the investment community to discuss the results and answer questions at 4:30 p.m. ET.Date & Time: Thursday, August 10 @ 4:30 p.m. ETDial In:Domestic callers (toll free): 844-887-9402International callers: 412-317-6798Canadian callers (toll free): 866-605-3852Live webcast: https://event.choruscall.com/mediaframe/webcast
- Platform Enables Customers to Manufacture mRNA with Substantial Reduction in dsRNA and Manufacturing Complexities; Integrable into Current mRNA Workflows -- Platform Currently Available Under Early Access Program -STONY BROOK, NY / ACCESSWIRE / July 13, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced that it has acquired Spindle Biotech Inc. ("Spindle"), an early-stage, private biotech company developing next-generation RNA manufacturing technologies. The acquisition uniquely leverages the Company's LinearDNA™ platform that enables the efficient chemical modification of DNA templates and the high bind
- linearDNA™ Gaining Momentum as a Differentiated DNA Template for mRNA Production, Company Identifies Early Development-Stage Acquisition Target to Potentially Expand Commercial Advantages -- Balance of CY23 Set Up for Multiple Value Inflection Points -- Conference Call/Webcast Scheduled for Today at 4:30 PM ET -STONY BROOK, NY / ACCESSWIRE / May 11, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced consolidated financial results for the second quarter of fiscal 2023 ended March 31, 2023.Commenting on the Company's quarterly performance, Dr. James A. Hayward, president and CEO, stated, "We made steady pr